Who Paid My Doc Search
Menu
Organisation paid for research Program year 2022 Source: CMS Open Payments

Suaimhneas PC

Neither a doctor nor a teaching hospital

Research payments

$1,137,680

238 payments

Through program year 2022, Suaimhneas PC is reported as receiving $1,137,680 in research payments, across 238 payments.

By program year

4 rows
Year Kind Amount Payments
2022 Research $13,245 10
2021 Research $452,882 91
2020 Research $262,590 70
2019 Research $408,963 67

Breakdown

Who paid Research payments · program years 2019–2022
  1. Acerta Pharma LLC $296,121 10 payments
  2. Pharmacyclics LLC, An AbbVie Company $171,130 53 payments
  3. AstraZeneca UK Limited $165,273 19 payments
  4. E.R. Squibb & Sons, L.L.C. $149,125 18 payments
  5. Roche Products Limited $97,775 11 payments
  6. EMD Serono, Inc. $97,090 41 payments
  7. Hoffmann-La Roche Limited $43,545 10 payments
  8. F. Hoffmann-La Roche AG $26,540 11 payments
  9. AstraZeneca Pharmaceuticals LP $19,050 1 payment
  10. Halozyme Inc $16,060 11 payments
Studies the money was for Research payments · program years 2019–2022
  1. A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase 3 Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects with High Risk Chronic Lymphocytic Leukemia $125,415 3 payments
  2. Phase III Study in Adjuvant Therapy in Renal Cell Carcinoma Patients $97,775 11 payments
  3. A Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Transarterial Chemoembolization (TACE) in Combination with either Durvalumab Monotherapy or Durvalumab plus Bevacizumab Therapy in Patients with Locoregional Hepatocellular Carcinoma $91,992 5 payments
  4. A Study of Bendamustine and Rituximab Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated Mantle Cell Lymphoma $81,271 4 payments
  5. Emr 100070-005 $65,310 11 payments
  6. This is a randomized open label multi center global Phase III study to assess the efficacy and safety of durvalumab plus tremelimumab combination therapy and durvalumab monotherapy versus sorafenib in the treatment of patients with no prior systemic therapy for unresectable HCC $56,503 2 payments
  7. A Phase 3, Randomized, Open-Label Study of Nivolumab Combined With Ipilimumab Versus Sunitinib Monotherapy in Subjects With Previously Untreated, Advanced or Metastatic Renal Cell Carcinoma $51,710 5 payments
  8. A Randomized, Multicenter, Open-Label, 3 Arm Phase 3 Study of Obinutuzumab in Combination with Chlorambucil, ACP-196 in Combination with Obinutuzumab, and ACP-196 Monotherapy in Subjects with Previously Untreated Chronic Lymphocytic Leukemia $46,635 3 payments
  9. Study of Ibrutinib and Rituximab in Treatment Naive Follicular Lymphoma $45,640 7 payments
  10. A Phase III Study in Cobimetinib Plus Atezolizumab Versus Pembrolizumab in Brafwt Melanoma Patients $43,545 10 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2022

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record